The Therapeutic Efficacy of I131-PSCA-mAb in Orthotopic Mouse Models of Prostate Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2013 Dec 17

PMID 24330823

Citations 6

Authors

Shengqiang Yu

Fan Feng

Ke Wang

Changping Men

Chunhua Lin

Qingzuo Liu

Diandong Yang

Zhenli Gao

Affiliations

Soon will be listed here.

Abstract

Background: Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I131 (I131-PSCA-mAb) in orthotopic mouse models of prostate cancer.

Methods: The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb were measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I131-PSCA-mAb distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured.

Results: The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached a maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. The invaded number of PC-3 and LNCaP cells treated with I131-PSCA-mAbe was significantly reduced (P < 0.01) compared with the control group. The ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in tumor-bearing nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with I131-PSCA-mAb was larger than that in the control group.

Conclusion: I131-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate cancer.

Citing Articles

Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.

Nayerpour Dizaj T, Doustmihan A, Sadeghzadeh Oskouei B, Akbari M, Jaymand M, Mazloomi M Cancer Cell Int. 2024; 24(1):135.

PMID: 38627732 PMC: 11020972. DOI: 10.1186/s12935-024-03320-6.

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.

Chen Q, Lu L, Ma W Cancers (Basel). 2022; 14(23).

PMID: 36497465 PMC: 9739567. DOI: 10.3390/cancers14235983.

Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.

Czerwinska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A Molecules. 2020; 25(7).

PMID: 32290196 PMC: 7181060. DOI: 10.3390/molecules25071743.

Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.

Yang N, Yao S, Liu D Oncol Lett. 2018; 16(1):276-284.

PMID: 29928412 PMC: 6006446. DOI: 10.3892/ol.2018.8635.

Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.

Mai T, Ma R, Li Z, Bi S Braz J Med Biol Res. 2016; 49(11):e5620.

PMID: 27783810 PMC: 5089234. DOI: 10.1590/1414-431X20165620.

References

Ahmad S, Casey G, Sweeney P, Tangney M, OSullivan G . Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther. 2009; 17(6):1101-8. PMC: 2835175. DOI: 10.1038/mt.2009.66. View

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 167(2 Pt 2):948-51; discussion 952. View

Han K, Seligson D, Liu X, Horvath S, Shintaku P, Thomas G . Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004; 171(3):1117-21. DOI: 10.1097/01.ju.0000109982.60619.93. View

Saffran D, Raitano A, Hubert R, Witte O, Reiter R, Jakobovits A . Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A. 2001; 98(5):2658-63. PMC: 30194. DOI: 10.1073/pnas.051624698. View

Sharkey R, Goldenberg D . Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin. 2006; 56(4):226-43. DOI: 10.3322/canjclin.56.4.226. View

La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P . Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol. 2009; 21(6):1323-1360. DOI: 10.1093/annonc/mdp530. View

Bander N, Nanus D, Milowsky M, Kostakoglu L, Vallabahajosula S, Goldsmith S . Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003; 30(5):667-76. DOI: 10.1016/s0093-7754(03)00358-0. View

Halabi S, Small E, Kantoff P, Kattan M, Kaplan E, Dawson N . Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7):1232-7. DOI: 10.1200/JCO.2003.06.100. View

Dadachova E, Nosanchuk J, Shi L, Schweitzer A, Frenkel A, Nosanchuk J . Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin. Proc Natl Acad Sci U S A. 2004; 101(41):14865-70. PMC: 522038. DOI: 10.1073/pnas.0406180101. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Moul J . Variables in predicting survival based on treating "PSA-only" relapse. Urol Oncol. 2003; 21(4):292-304. DOI: 10.1016/s1078-1439(03)00103-0. View

12.

Blesa J, Godoy M, Esparcia M, Molla S, Magan B, Ortells J . PSA Response to Lenalidomide Therapy in a Pre-Treated Patient with Metastatic Prostate Cancer Refractory to Hormones and Chemotherapy: A Case Report. Case Rep Oncol. 2012; 5(1):181-6. PMC: 3364036. DOI: 10.1159/000336481. View

13.

Gu Z, Thomas G, Yamashiro J, Shintaku I, dOrey F, Raitano A . Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000; 19(10):1288-96. DOI: 10.1038/sj.onc.1203426. View

14.

Zalutsky M, Pozzi O . Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2005; 48(4):289-96. View

15.

Saeki N, Gu J, Yoshida T, Wu X . Prostate stem cell antigen: a Jekyll and Hyde molecule?. Clin Cancer Res. 2010; 16(14):3533-8. PMC: 2905486. DOI: 10.1158/1078-0432.CCR-09-3169. View

16.

Chamarthy M, Williams S, Moadel R . Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'. Yale J Biol Med. 2011; 84(4):391-407. PMC: 3238311. View

17.

Sternberg C . Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. Ann Oncol. 2008; 19 Suppl 7:vii91-5. DOI: 10.1093/annonc/mdn473. View

18.

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

19.

Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S . Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol. 2013; 7:1-12. PMC: 3547543. DOI: 10.4137/CMO.S7256. View

20.

Lam J, Yamashiro J, Shintaku I, Vessella R, Jenkins R, Horvath S . Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005; 11(7):2591-6. DOI: 10.1158/1078-0432.CCR-04-1842. View